Keppra XR
Phase 3Small molecule
UCBKeppra XR is one of 74 small molecule programs targeting Seizure. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
221 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsPhase 3
Dayvigo
EisaiPhase 3
Depacon
AbbViePhase 3
Zonegran
AAzurity Pharmaceuticals
Phase 3
Fintepla
IImmedica Pharma AB
Phase 3
Actemra
RochePhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
GWP42003-P
Jazz PharmaceuticalsPhase 3
Immunoglobulin
SanofiPhase 3
Carisbamate
SSK Life Science, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Seizure2 trials
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Keppra XR. EMBL-EBI & Wellcome Sanger Institute.
- [4]